SCHEDULE: FMR LLC Discloses 14.4% Stake in Tyra Biosciences

FMR LLC, through its affiliates, has reported beneficial ownership of 14.4% of Tyra Biosciences Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC, a significant investment management firm, has filed a Schedule 13G indicating its beneficial ownership of Tyra Biosciences Inc. common stock.
• As of March 31, 2026, FMR LLC and its related entities beneficially owned 7,747,647.96 shares, representing 14.4% of the outstanding common stock.
• The filing indicates that FMR LLC has sole voting power over 7,741,957.00 shares and sole dispositive power over 7,747,647.96 shares.
• Abigail P. Johnson, Director, Chairman, and CEO of FMR LLC, is also noted in relation to the filing, with members of the Johnson family being predominant owners of FMR LLC.
• Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Strategic Advisers LLC are identified as entities within the FMR reporting group.
• Fidelity OTC Portfolio holds a specific interest of 2,694,729.00 shares, or 5.0% of the total outstanding common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it is a routine ownership disclosure and does not provide performance or strategic information about Tyra Biosciences itself.

Positives

• Significant institutional ownership by FMR LLC, a reputable investment manager, can signal confidence in the company's long-term prospects.
• The substantial stake held by FMR LLC suggests a strong belief in Tyra Biosciences' value proposition.

Negatives

• The filing does not contain financial performance data or operational updates, making it difficult to assess the company's current health.
• The information is limited to ownership disclosure, providing no insight into the strategic direction or challenges of Tyra Biosciences.

Risks

• The concentration of ownership with a large institutional investor could lead to significant selling pressure if that investor decides to divest.
• While not explicitly stated as a risk in this filing, any future changes in FMR LLC's investment strategy could impact Tyra Biosciences' stock.

Future Outlook

This filing is purely an ownership disclosure and does not contain any forward-looking statements or guidance regarding Tyra Biosciences' future performance.

Management Comments

• Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
• The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G are common in the biotechnology sector, reflecting active portfolio management by large investment firms seeking growth opportunities. The substantial stake by FMR LLC suggests Tyra Biosciences is a notable holding within their investment universe.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can influence market perception and trading liquidity. Future actions by FMR LLC could impact share price.
• Management: The presence of a large, active investor like FMR LLC may imply a degree of oversight or influence on corporate strategy.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Monitor future filings from FMR LLC and Tyra Biosciences for any changes in ownership or strategic developments.

Key Dates

Keywords

Tyra Biosciences, FMR LLC, Schedule 13G, Institutional Ownership, Beneficial Ownership, Common Stock, Fidelity, Abigail P. Johnson, SEC Filing